New and integrated approaches to successful accelerated drug development

Drug Information Journal

Volumn 33, Issue 3, 1999, Pages 699-710

  Clemento, Anthony ^a  

^a 206 Carnegie Center   (United States)

Author keywords

Accelerated drug development; Clinical testing; Drug discovery; Preclinical testing; Product development; Research

Indexed keywords

PROTEINASE INHIBITOR;

ALGORITHM; CLINICAL TRIAL; DRUG CONTROL; DRUG COST; DRUG DETERMINATION; DRUG EFFICACY; DRUG FORMULATION; DRUG INDUSTRY; DRUG LABELING; DRUG PROGRAM; DRUG QUALITY; DRUG SAFETY; DRUG SCREENING; EVALUATION; PRIORITY JOURNAL; REVIEW; TIME; TOXICITY TESTING;

EID: 0032802777     PISSN: 00928615     EISSN: None     Source Type: Journal    
DOI: 10.1177/009286159903300306     Document Type: Review

References (9)

1. DeMasi JA. Trends in drug development: costs, times, and risks. Drug Inf J. 1995;29:375-384.
2. Lin JH, Lu AY. Role of pharmacokinetics and metabolism in drug discovery and development. Pharmacol Rev. 1997;49:403-449.
3. DeMasi JA, Hansen RW, Grabowski HG, Lasagna L. Research and development costs for new drugs by therapeutic category. Pharma Econ. 1995;7:152-169.
4. Kleinberg ML, Wanke LA. New approaches and technologies in drug design and discovery. Am J Health Syst Pharm. 1995;52:1323-1336; 1341-1343.
5. Andersen Consulting. Pharmaceutical & Medical Products Executive Briefing. Drug Discovery: Innovation and Productivity. 1998:1-26.
6. Bugg CE, Carson WM, Montgomery JA. Drugs by design. Sci Am. 1993;269:92-98.
7. Ziai MR, Beer B. Making business sense of science with rational drug design. Pharm Exec. 1990;10:40, 42, 44, 46.
8. Hayes AH, Jr. Safety considerations in product development. Drug Saf. 1990;5(suppl):24-26.
9. Establishment of Prescription Drug User Fee Rates for Fiscal Year 1998. Federal Register. 1997;62(236): 64849-64851.